a public good project by the
Synthesis
Company
of California

© 2026

Kenneth S. Thress | doi.page

0 works0 citations0 h-index

Kenneth S. Thress

AstraZeneca (South Korea)(KR)AstraZeneca (United States)(US)

Publications by Year

Research Areas

Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, HER2/EGFR in Cancer Research, Colorectal Cancer Treatments and Studies, Lymphoma Diagnosis and Treatment

Most-Cited Works

→ Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M(2015)1,518 cited
→ Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer(2016)838 cited
→ Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity(2016)707 cited
→ Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib(2018)677 cited
→ Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer(2017)526 cited
→ EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291(2015)493 cited

→ Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation.(1996)489 cited

→ TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer(2020)433 cited

→ Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models(2015)294 cited

→ Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses(2017)184 cited